How Multi-Specialty Physician Groups Should Structure Denial Management in 2026

The Multi-Specialty Denial Problem Is Different From a Single-Specialty One

A single-specialty practice can get away with informal denial handling. One or two billers learn the quirks of a handful of payers, memorize the documentation a handful of procedure codes require, and appeal accordingly. It's not efficient, but it's manageable.

Multi-specialty groups don't have that luxury. A group spanning primary care, orthopedics, neurology, and dermatology is really running four or five different denial businesses under one roof. Each specialty has its own dominant denial categories, its own documentation standards, and its own relationship to medical necessity review. A denial workflow built around one specialty's patterns will systematically underperform for the others.

The result, in practices that haven't addressed this deliberately, is usually a patchwork: pockets of good process in whichever specialty happens to have an experienced biller, and inconsistent, reactive handling everywhere else. Denial data doesn't roll up cleanly. Nobody can say with confidence which specialty has the worst overturn rate, or why.

Why Centralized-But-Specialty-Aware Beats Fully Centralized or Fully Decentralized

Two structures fail predictably. Fully decentralized denial handling — where each specialty's billing staff operates independently — loses economies of scale. Best practices don't transfer, tooling doesn't get shared, and leadership loses visibility into aggregate performance.

Fully centralized handling, where one general billing team appeals everything regardless of specialty, fails differently. Generalist billers lack the clinical context to write a strong medical necessity argument for a neurology denial one hour and an orthopedic bundling dispute the next. Appeal quality drops, and overturn rates suffer.

The structure that tends to work is centralized process with specialty-aware execution: one shared intake process, one shared tracking system, one shared set of deadlines and escalation rules — but appeal content that's informed by specialty-specific context, whether that comes from specialty-trained staff, specialty-specific documentation checklists, or tooling that adapts to the clinical area.

Building the Org Chart: Who Owns What

In practice, this usually means three roles. A denial management lead owns the process end-to-end: intake, tracking, deadline management, and reporting to leadership. This person doesn't need deep clinical knowledge in every specialty — they need process discipline and visibility into the full portfolio.

Specialty liaisons — often a senior biller or coder within each specialty's billing pod — own the clinical and coding judgment calls: what documentation an appeal needs, whether a denial is worth appealing at all, and what the medical necessity argument should say.

A billing operations or RCM leadership role owns the pattern recognition across specialties — noticing, for instance, that a payer is denying a particular code across three different specialties, which suggests a systemic issue worth escalating rather than five individual disputes.

The Data Layer: Tracking Denials Across Specialties Without Losing Specialty-Level Detail

The most common failure point isn't the appeal writing — it's the tracking. Groups often end up with a spreadsheet per specialty, which makes portfolio-level reporting nearly impossible. Leadership ends up asking 'how are we doing on denials?' and getting five different answers in five different formats.

A workable model tracks denials in one system with specialty, payer, denial reason, dollar value, and outcome as fields on every record — not as separate tracking systems per specialty. That single structure is what lets you answer both the specialty-specific question ('how is orthopedics doing against UHC?') and the portfolio question ('what's our overall overturn rate?') from the same data.

A Practical Model for 2026

For groups building this out now, a reasonable sequence is: standardize the intake and tracking process first, since that's where most of the chaos lives and it's the least disruptive to change. Second, formalize specialty liaison roles, even informally, so appeal quality doesn't depend entirely on who happens to be available. Third, start reviewing cross-specialty denial patterns monthly, not just specialty-by-specialty — that's where the highest-leverage insights tend to show up, particularly when the same payer is denying similar things across different clinical areas.

None of this requires a large team or a large technology investment to start. It requires treating denial management as a portfolio discipline rather than a collection of specialty-level habits.